> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Liquidia To Pay United Therapeutics $330.4 Million And Pull Yutrepia's Lung-Disease Label
- URL: https://www.bullished.co/liquidia-to-pay-united-therapeutics-330-4-million-and-pull-yutrepias-lung-disease-label-ea223a0f/
- Published: 2026-10-14T11:17:23.000Z
- Updated: 2026-10-28T21:51:21.000Z
- Description: The 8-K says $185 million is due within 30 business days, with $145.4 million to follow in two installments.
- Author: Matteo Parrino
- Tags: SEC Filings, UTHR, Industry: Healthcare

Liquidia Technologies agreed to pay [United Therapeutics](https://www.bullished.co/tag/uthr/) an aggregate [$330.4 million](https://www.sec.gov/Archives/edgar/data/0001082554/000110465926115723/tm2627546d1%5F8k.htm?ref=bullished.co) and to seek removal of the lung-disease indication from its inhaled drug Yutrepia, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Wednesday. The settlement agreement is dated Tuesday and covers the patent fights and most of the trade-secrets litigation between the two companies.

## What the 8-K says about the money

Of the total, $185 million is described as an estimate of damages for past Yutrepia sales for pulmonary hypertension associated with interstitial lung disease (PH-ILD). It is due within 30 business days of the agreement. The exhibit ties that sum to sales from June 2, 2025 to the execution date.

The other $145.4 million is an agreed estimate of damages for continuing PH-ILD sales after signing. It is payable in two equal installments of $72.7 million. The 8-K body gives the due dates as February 1, 2027 and April 30, 2027, while the [settlement agreement exhibit](https://www.sec.gov/Archives/edgar/data/0001082554/000110465926115723/tm2627546d1%5Fex99-1.htm?ref=bullished.co) says January 31, 2027 and April 30, 2027.

The exhibit also requires Liquidia to deliver a letter of credit from a bank acceptable to United Therapeutics within ten business days. If it fails to do so, United Therapeutics may terminate the agreement.

Going the other way, United Therapeutics will pay Liquidia $10.0 million within 30 business days to resolve the RareGen and Sandoz antitrust litigation.

## What Liquidia must change

Liquidia must immediately file with the FDA to remove PH-ILD from Yutrepia's labeling. Until the FDA approves, it may keep selling under the current label, but must stop all marketing, promotion and detailing for PH-ILD. Once approved, it must stop selling Yutrepia bearing that indication.

Afterward it may promote Yutrepia only to practitioners who, to its knowledge, treat pulmonary arterial hypertension. It must also send letters telling prescribers that PH-ILD patients should move to another therapy, and ask payers to deny prior authorization for PH-ILD use. Referral forms must carry a checkbox certifying Group 1 PAH.

Liquidia must also end the PH-ILD cohorts of its ASCENT trial as promptly as practicable. It may not publish or circulate data from those cohorts until after the '327 patent expires.

## What it resolves, and what it does not

The parties will seek dismissal with prejudice of the covered cases within ten days after United Therapeutics receives the $185 million. That includes the Delaware case in which the court held Liquidia liable on September 30 for infringing the '327 patent, which expires February 3, 2042.

United Therapeutics may keep pursuing its trade-secrets claims against Robert Roscigno, a former Liquidia executive. The releases take effect only after payments, a Liquidia officer's declaration that PH-ILD sales have ceased following label approval, and dismissals.

On October 7 the Third Circuit affirmed United Therapeutics' summary judgment win on the antitrust claims. It also vacated the $61.6 million damages award to Sandoz and sent the contract and tortious-interference claims back for further proceedings. Liquidia must obtain any needed third-party consents, including Sandoz's.

UTHR closed at $543.40 on Tuesday, down 1.22%, before the filing appeared.

Next up are the FDA's ruling on Liquidia's label amendment and the $185 million payment, after which the dismissals are due within ten days.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — UNITED THERAPEUTICS Corp (UTHR)](https://www.sec.gov/Archives/edgar/data/0001082554/000110465926115723/tm2627546d1%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2627546d1\_ex99-1.htm — UNITED THERAPEUTICS Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001082554/000110465926115723/tm2627546d1%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Liquidia Settles United Therapeutics Suits With $380.7M Deal - Law360](https://www.law360.com/articles/2537586/liquidia-settles-united-therapeutics-suits-with-380-7m-deal?ref=bullished.co) — law360.com

### More on United Therapeutics

- [United Therapeutics Authorizes Another $2 Billion Buyback, Separate From Its Running Repurchase](https://www.bullished.co/united-therapeutics-authorizes-another-2-billion-buyback-separate-from-its-running-53a2e6b6/)

[All United Therapeutics (UTHR) coverage →](https://www.bullished.co/tag/uthr/)